SCHEMBL25613106

SCHEMBL25613106

CC(C)(C)c1cc2cc[nH]c2nc1OCC1CS(=O)(=O)C1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FEN1 P39748 1/20 0.33
▸ CHRNA7 P36544 1/20 0.32
▸ CTSD P07339 1/20 0.31
▸ BACE1 P56817 1/20 0.31
▸ CNR2 P34972 2/20 0.31
▸ CDK8 P49336 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ CCNT1 O60563 1/20 0.31
▸ CDK1 P06493 1/20 0.31
▸ CCNB1 P14635 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ CDK7 P50613 1/20 0.31
▸ CDK9 P50750 1/20 0.31
▸ CCNH P51946 1/20 0.31
▸ CDK5 Q00535 1/20 0.31
▸ FGFR1 P11362 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613105 0.91 JAK2 (0.35) FEN1CHRNA7CNR2ALDH1A1MAPT
SCHEMBL25613092 0.84 CDK2 (0.40) CCNT1CDK1CCNB1CDK2CDK7
SCHEMBL25613094 0.84 CDK2 (0.38) FEN1CNR2CCNT1CDK1CCNB1
SCHEMBL25613190 0.82 CTSD (0.32) FEN1CTSDBACE1CDK8ALDH1A1
SCHEMBL25613097 0.79 CHRNB4 (0.39) —
SCHEMBL25613088 0.78 GRM4 (0.40) CNR2CCNT1CDK1CCNB1CDK2
SCHEMBL25613037 0.77 FEN1 (0.39) FEN1CDK8CDK1FGFR1KDR
SCHEMBL25613043 0.74 CDK1 (0.39) FEN1CDK8HTTCDK1CCNB1
SCHEMBL25613050 0.74 FEN1 (0.39) FEN1CDK8GAACDK1CDK2
SCHEMBL25613169 0.72 BRD4 (0.40) FEN1CDK8FGFR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 FEN1 1864/4885CHRNA7 4866/4885CTSD 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback